In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price ...
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $109.00. The company’s ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DOJoPAWP.js ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Healthcare Services (HCSG – Research Report) and ...
See the top stocks recommended by analysts >> Nektar Therapeutics (NKTR) B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics today and set a price target of $4.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results